methylene blue has been researched along with Cognition Disorders in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Nair, A | 1 |
| Abrao, J; Baker, GB; Balista, PA; Chaves, C; Dursun, SM; Evora, PR; Guimaraes, FS; Hallak, JE; Kandratavicius, L; Leite, JP; Maia-de-Oliveira, JP; Rodrigues, AJ; Wolf, DC | 1 |
| Cadinu, D; Goll, P; Hochgräfe, K; Könen, S; Mandelkow, E; Mandelkow, EM; Matenia, D; Morellini, F; Petrova, O; Pickhardt, M; Sydow, A | 1 |
| Deiana, S; Harrington, CR; Riedel, G; Wischik, CM | 1 |
| Lorke, DE; Oz, M; Petroianu, GA | 1 |
| Caccamo, A; Medina, DX; Oddo, S | 1 |
| Gonzalez-Lima, F; Riha, PD; Rojas, JC | 1 |
1 review(s) available for methylene blue and Cognition Disorders
| Article | Year |
|---|---|
Methylene blue and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Humans; Methylene Blue; Neurofibrillary Tangles; Neurons | 2009 |
6 other study(ies) available for methylene blue and Cognition Disorders
| Article | Year |
|---|---|
Using intravenous methylene blue to reduce postoperative cognitive disorders in elderly patients- a methodical approach.
Topics: Aged; Cognition; Cognition Disorders; Humans; Methylene Blue; Postoperative Period | 2021 |
Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.
Topics: Acute Disease; Animals; Antipsychotic Agents; Cognition Disorders; Dietary Sucrose; Disease Models, Animal; Exploratory Behavior; Male; Methylene Blue; Motor Activity; Nitric Oxide Donors; Nitroglycerin; Nitroprusside; Rats, Wistar; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Taste Perception; Treatment Outcome | 2015 |
Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.
Topics: Animals; Behavior, Animal; Cognition; Cognition Disorders; Disease Models, Animal; Enzyme Inhibitors; Humans; Maze Learning; Memory; Methylene Blue; Mice; Mice, Inbred C57BL; Mice, Transgenic; tau Proteins; Tauopathies; Time Factors; Treatment Outcome | 2015 |
Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Maze Learning; Memory; Methylene Blue; Mice; Muscarinic Antagonists; Nootropic Agents; Phenylcarbamates; Postural Balance; Rivastigmine; Scopolamine; Space Perception; Swimming | 2009 |
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Cognition Disorders; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Immunohistochemistry; Male; Methylene Blue; Mice; Mice, Transgenic; Proteasome Endopeptidase Complex; tau Proteins | 2011 |
Beneficial network effects of methylene blue in an amnestic model.
Topics: Amnesia; Animals; Cognition Disorders; Enzyme Inhibitors; Gyrus Cinguli; Male; Methylene Blue; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Sodium Azide | 2011 |